Xizang Weixinkang Pharmaceutical Co., Ltd. (603676.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 8.86

From 52W high−28.82%

Volume1.57M

Market capCNY 3.98B

P/E (TTM)17.1x

P/S (TTM)3.3x

Div yield3.75%

Key dataSep 18, 2026

Open

CNY 8.86

From 52W high

−28.82%

Volume

1.57M

Market cap

CNY 3.98B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.5x

P/E (TTM)

17.1x

RSI (14)

40.6

MomentumView details →

1D Return

−2.04%

YTD Return

−17.11%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

17.1x

EV/EBITDA

10.5x

EV/Sales

3.0x

P/S (TTM)

3.3x

P/B (TTM)

2.7x

ProfitabilityView details →

Gross Margin

61.51%

Net Margin

18.64%

EBITDA Margin

29.06%

ROE (TTM)

14.03%

ROA (TTM)

11.11%

Asset Turnover

0.61x

GrowthView details →

Revenue YoY

−9.08%

EPS YoY

−8.67%

FCF YoY

−43.18%

Revenue CAGR 3Y

−6.70%

EPS CAGR 3Y

+9.61%

EBITDA YoY

—

MomentumView details →

1D Return

−2.04%

YTD Return

−17.11%

1Y Return

−26.48%

RSI (14)

40.6

vs 50D SMA

−3.34%

vs 200D SMA

−13.06%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.74x

Quick Ratio

3.58x

Div Yield

3.75%

Div Rate

CNY 0.33

Div Growth 1Y

−26.85%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.16B

Net Income (TTM)

216.65M

Op. CF (TTM)

223.03M

Latest newsMore news →

Weixinkang's wholly owned subsidiary Inner Mongolia Baiyi Pharmaceutical received a drug registration certificate from the National Medical Products Administration for water-soluble vitamins for injection, deemed equivalent to passing consistency evaluation.10d ago

Weixin Kang's wholly-owned subsidiary Yangpu Jingtai Pharmaceutical received approval from China's National Medical Products Administration for a supplementary application for Potassium Aspartate Injection, adding a new specification and deemed to pass consistency evaluation.20d ago

Similar companies

Shandong Xinhua Pharmaceutical Company Limited00719.HK Indivior Pharmaceuticals IncINDV 灵康药业603669.SH 司太立603520.SH Xuanzhubio-b02575.HK 太龙药业600222.SH Find similar companies →

Latest newsMore news →

Weixinkang's wholly owned subsidiary Inner Mongolia Baiyi Pharmaceutical received a drug registration certificate from the National Medical Products Administration for water-soluble vitamins for injection, deemed equivalent to passing consistency evaluation.10d ago Weixin Kang's wholly-owned subsidiary Yangpu Jingtai Pharmaceutical received approval from China's National Medical Products Administration for a supplementary application for Potassium Aspartate Injection, adding a new specification and deemed to pass consistency evaluation.20d ago Weixinkang announced its 2026 first-half results: net profit attributable to shareholders was 143 million yuan, down 21.81% year-on-year.24d ago